Top Industry Leaders in the Geographic Atrophy GA Market
Latest Geographic Atrophy Companies Update:
Second FDA Approval for GA Treatment: In August 2023, Iveric Bio received FDA approval for Izervay (avacincaptad pegol), the second ever-approved treatment for GA after Syfovre (pegcetacoplan injection). This offers increased options and hope for patients.
Focus on Novel Treatment Approaches: Companies like Apellis Pharmaceuticals and Gyroscope Therapeutics are researching and developing gene therapy and stem cell-based therapies for GA, potentially offering long-term solutions.
Clinical Trial Momentum: Several promising Phase 3 clinical trials are underway for potential GA treatments, including NGM Bio's NGM621 and Alkeus Pharmaceuticals' Gildeuretinol.
Diagnostic Advancements: New imaging technologies like swept-source Optical Coherence Tomography (OCT) are improving early detection and monitoring of GA progression, leading to timely treatment initiation.
List of Geographic Atrophy Key companies in the market
- Apellis Pharmaceuticals, Inc. (US)
- Iveric Bio (US)
- Alkeus Pharmaceuticals, Inc. (US)
- Hemera Biosciences LLC (US)
- Allegro Ophthalmics, LLC (US)
- Stealth BioTherapeutics (Cayman Islands)
- Gyroscope Therapeutics Limited (UK)
- F. Hoffmann-La Roche AG (Switzerland)
- Genentech, Inc. (US)
- Gensight Biologics SA (France)